financetom
Business
financetom
/
Business
/
Apple turns to third parties for 'buy now, pay later' after sunsetting product
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Apple turns to third parties for 'buy now, pay later' after sunsetting product
Jun 18, 2024 3:07 PM

(Reuters) - Although Apple is discontinuing its buy now, pay later service launched last year, the company is sticking with the product, with a successor to the offering launching later this year via third-parties like Affirm.

Buy now, pay later (BNPL) exploded in popularity as the COVID-19 pandemic forced more shoppers online, and the product has continued to resonate with consumers. BNPL loans drove $75 billion in online spending in 2023, up 14.3% from 2022, according to Adobe Analytics.

In a statement on Monday, Apple ( AAPL ) said its new solution "will enable us to bring flexible payments to more users, in more places across the globe in collaboration with Apple Pay-enabled banks and lenders." It did not comment further about why it was ending its independent BNPL offering.

Existing users of the BNPL service, Apple Pay Later will still be able to manage and pay open loans via the Wallet app, the company said.

Apple ( AAPL ) announced last week that Apple Pay users would be able to access new installment loan offerings this fall, including the ability to apply for BNPL loans directly through Affirm when they check out with Apple Pay. Customers will also be able to access installments from credit and debit cards, the tech giant said.

Analysts had viewed Apple's ( AAPL ) original BNPL product as a competitor to BNPL providers like Affirm. It offered customers the ability to buy products and pay in four interest-free installments for items up to $1,000. Affirm offers users the option to pay for products in two or four installments, as well as monthly installments for higher-cost items.

"To me, this sounds a lot like what we see happening with debit cards," said Sean Gelles, director of payments intelligence at J.D. Power. "Regardless of which debit card a consumer has funding their purchases, as long as they use Apple Pay, it's Apple ( AAPL ) that owns the experience."

Gelles added that if Apple's ( AAPL ) new portfolio of BNPL products are delivered via Apple Pay there would be "minimal risk for Apple ( AAPL ) as they will thereby retain the relationship with the customer."

While Apple ( AAPL ) could choose to partner with additional BNPL providers in the future -- such as Affirm rival Klarna -- a source familiar with the matter highlighted Affirm's technology and underwriting expertise, as well as the company's choice to not charge users late fees.

Klarna declined to comment.

Shares in Affirm were last down 0.7% on the day, a move that one analyst chalked up to weaker-than-expected retail sales data in May.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss
Esperion Therapeutics Shares Fall After Reporting Wider Than Expected Q2 Loss
Aug 12, 2024
03:45 PM EDT, 08/12/2024 (MT Newswires) -- Esperion Therapeutics ( ESPR ) shares were down nearly 8% in recent Monday trading after the company reported a wider-than-expected Q2 net loss. The company reported a Q2 net loss of $0.33 per diluted share, compared with a loss of $0.46 a year earlier. Analysts polled by Capital IQ expected a $0.18 loss....
Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition
Update: Eli Lilly Looking to Issue Debt for Morphic Acquisition
Aug 12, 2024
03:45 PM EDT, 08/12/2024 (MT Newswires) -- (Updates to reflect Eli Lilly ( LLY ) declined comment to MT Newswires) Eli Lilly ( LLY ) filed a prospectus Monday to raise debt for its $3.2 billion acquisition of Morphic. According to a securities filing, the pharma company is looking to issue five separate series of notes to raise $5 billion...
Portillo's Insider Sold Shares Worth $679,675, According to a Recent SEC Filing
Portillo's Insider Sold Shares Worth $679,675, According to a Recent SEC Filing
Aug 12, 2024
03:56 PM EDT, 08/12/2024 (MT Newswires) -- Michael Osanloo, Director, President & CEO, on August 09, 2024, sold 66,052 shares in Portillo's (PTLO) for $679,675. Following the Form 4 filing with the SEC, Osanloo has control over a total of 79,041 shares of the company, with 79,041 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1871509/000187150924000105/xslF345X03/wk-form4_1723492418.xml Price: 10.82, Change: +0.11, Percent Change: +1.03...
Novartis loses initial bid to block generic of best-selling heart drug
Novartis loses initial bid to block generic of best-selling heart drug
Aug 12, 2024
Aug 12 (Reuters) - Novartis failed to convince a Delaware federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court decision issued on Monday. U.S. District Judge Richard Andrews ruled that Novartis' chance of winning its patent-infringement lawsuit challenging the generic was too low to justify halting...
Copyright 2023-2026 - www.financetom.com All Rights Reserved